<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Moulopoulos, L.A.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A new pet for myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449584881&amp;doi=10.1182%2fblood-2009-06-224196&amp;partnerID=40&amp;md5=d353f49fecda688a3ef417c36e08dddf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">114</style></volume><pages><style face="normal" font="default" size="100%">2007 - 2008</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">In this issue of Blood, Bartel and colleagues report the independent predictive value of the PET/CT and of the FDG suppression before transplantation in newly diagnosed myeloma patients who were treated using the TT3 regimen.</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><notes><style face="normal" font="default" size="100%">Cited By :4Export Date: 21 February 2017</style></notes></record></records></xml>